longwood-fund
(2)
Carbon Biosciences
Carbon Biosciences is a Waltham, Massachusetts preclinical genetic-medicine company building gene therapies on non-AAV parvovirus vectors. Founded by Longwood Fund with gene-therapy pioneers John Engelhardt and Robert Kotin, it uses a proprietary vector engine (PAVE) to design capsids from the broad parvovirus family - including human bocavirus - that carry larger genetic payloads, target specific tissues, and provoke little pre-existing immunity, opening the door to re-dosing. Its lead program targets cystic fibrosis by delivering the full-length CFTR gene to the lung, with a second vector aimed at cardiac disease.
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.